Dan Atar1, Håkan Arheden2, Alain Berdeaux3, Jean-Louis Bonnet4, Marcus Carlsson2, Peter Clemmensen5, Valérie Cuvier6, Nicolas Danchin7, Jean-Luc Dubois-Randé8, Henrik Engblom2, David Erlinge9, Hüseyin Firat10, Sigrun Halvorsen11, Henrik Steen Hansen12, Wilfried Hauke6, Einar Heiberg2, Sasha Koul9, Alf-Inge Larsen13, Philippe Le Corvoisier8, Jan Erik Nordrehaug14, Franck Paganelli15, Rebecca M Pruss6, Hélène Rousseau16, Sophie Schaller6, Giles Sonou17, Vegard Tuseth14, Julien Veys6, Eric Vicaut16, Svend Eggert Jensen18. 1. Department of Cardiology B, Oslo University Hospital Ullevål, and Faculty of Medicine, University of Oslo, Oslo, Norway dan.atar@online.no. 2. Department of Clinical Physiology, Lund University, Skåne University Hospital, Lund, Sweden. 3. Université Paris Est Val de Marne, Créteil, France. 4. Assistance Publique Hôpitaux de Marseille, Hôpital La Timone, Marseille, France. 5. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 6. Trophos SA, Luminy Biotech Enterprises, Marseille, France. 7. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. 8. Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France. 9. Department of Cardiology, Lund University, Lund, Sweden. 10. Firalis SAS, Huningue, France. 11. Department of Cardiology B, Oslo University Hospital Ullevål, and Faculty of Medicine, University of Oslo, Oslo, Norway. 12. Department of Cardiology B, Odense University Hospital, Odense, Denmark. 13. Department of Cardiology, Stavanger University Hospital, Stavanger, Norway. 14. Department of Clinical Science, University of Bergen, Bergen, Norway. 15. Department of Cardiology, Hospital Nord, Marseille, France. 16. Clinical Research Unit, Lariboisière Hospital, Paris, France. 17. Mobile Health, Paris, France. 18. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Abstract
AIM: The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI). METHODS:Patients presenting with STEMI within 6 h of the onset of pain randomly receivedTRO40303 (n = 83) or placebo (n = 80) via i.v. bolus injection prior to balloon inflation during primary percutaneous coronary intervention in a double-blind manner. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and for troponin I (TnI) over 3 days. Secondary endpoints included measures of infarct size using cardiac magnetic resonance (CMR) and safety outcomes. RESULTS: The median pain-to-balloon time was 180 min for both groups, and the median (mean) door-to-balloon time was 60 (38) min for all sites. Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. There were no significant differences in the CMR-assessed myocardial salvage index (1-infarct size/myocardium at risk) (mean 52 vs. 58% with placebo, P = 0.1000), mean CMR-assessed infarct size (21.9 g vs. 20.0 g, or 17 vs. 15% of LV-mass) or left ventricular ejection fraction (LVEF) (46 vs. 48%), or in the mean 30-day echocardiographic LVEF (51.5 vs. 52.2%) between TRO40303 and placebo. A greater number of adjudicated safety events occurred in the TRO40303 group for unexplained reasons. CONCLUSION: This study in STEMI patients treated with contemporary mechanical revascularization principles did not show any effect of TRO40303 in limiting reperfusion injury of the ischaemic myocardium. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIM: The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI). METHODS:Patients presenting with STEMI within 6 h of the onset of pain randomly received TRO40303 (n = 83) or placebo (n = 80) via i.v. bolus injection prior to balloon inflation during primary percutaneous coronary intervention in a double-blind manner. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and for troponin I (TnI) over 3 days. Secondary endpoints included measures of infarct size using cardiac magnetic resonance (CMR) and safety outcomes. RESULTS: The median pain-to-balloon time was 180 min for both groups, and the median (mean) door-to-balloon time was 60 (38) min for all sites. Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. There were no significant differences in the CMR-assessed myocardial salvage index (1-infarct size/myocardium at risk) (mean 52 vs. 58% with placebo, P = 0.1000), mean CMR-assessed infarct size (21.9 g vs. 20.0 g, or 17 vs. 15% of LV-mass) or left ventricular ejection fraction (LVEF) (46 vs. 48%), or in the mean 30-day echocardiographic LVEF (51.5 vs. 52.2%) between TRO40303 and placebo. A greater number of adjudicated safety events occurred in the TRO40303 group for unexplained reasons. CONCLUSION: This study in STEMI patients treated with contemporary mechanical revascularization principles did not show any effect of TRO40303 in limiting reperfusion injury of the ischaemic myocardium. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Joseph Allencherril; Yama Fakhri; Henrik Engblom; Einar Heiberg; Marcus Carlsson; Jean-Luc Dubois-Rande; Sigrun Halvorsen; Trygve S Hall; Alf-Inge Larsen; Svend Eggert Jensen; Hakan Arheden; Dan Atar; Peter Clemmensen; Maria Sejersten Ripa; Yochai Birnbaum Journal: Ann Noninvasive Electrocardiol Date: 2018-07-04 Impact factor: 1.468
Authors: Massimo Bonora; Mariusz R Wieckowski; David A Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi Journal: Nat Rev Cardiol Date: 2019-01 Impact factor: 32.419
Authors: Robert A Kloner; David A Brown; Marie Csete; Wangde Dai; James M Downey; Roberta A Gottlieb; Sharon L Hale; Jianru Shi Journal: Nat Rev Cardiol Date: 2017-07-27 Impact factor: 32.419
Authors: Mohammad Javad Hajipour; Mehdi Mehrani; Seyed Hesameddin Abbasi; Ahmad Amin; Seyed Ebrahim Kassaian; Jessica C Garbern; Giulio Caracciolo; Steven Zanganeh; Mitra Chitsazan; Haniyeh Aghaverdi; Seyed Mehdi Kamali Shahri; Aliakbar Ashkarran; Mohammad Raoufi; Holly Bauser-Heaton; Jianyi Zhang; Jochen D Muehlschlegel; Anna Moore; Richard T Lee; Joseph C Wu; Vahid Serpooshan; Morteza Mahmoudi Journal: Chem Rev Date: 2019-09-06 Impact factor: 60.622